iShares MSCI Pacific ex Japan ETF EPP
Set alert
55.80 USD -0.03 -0.05%
At close · Oct 30
55.80 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
55.58 Day range 55.89
48.96 52-week range 58.55
- YTD
- +10.56%
- 1 year
- +8.64%
- Open
- 55.85
- Prev close
- 55.83
- Mkt cap
- 2.24B
- Vol
- 467.79K
- Avg vol
- 230.55K
- EPS
- 2.99
- P/E
- 18.67
- Div yield
- 0.00%
More statistics
- Low
- 55.58
- High
- 55.89
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 56.04
- 200-d avg
- 55.14
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 18.70
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 56.04
- 200-day average
- 55.14
Analyst view
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
About iShares MSCI Pacific ex Japan ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index consists of stocks from the following four countries or regions: Australia, Hong Kong, New Zealand and Singapore. The underlying index include large- and mid-capitalization companies and may change over time. The fund is non-diversified.
News
- Disc Medicine (IRON) Achieves Positive Phase 3 Trial Results for EPP Treatment
- Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)
- Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)
- iShares MSCI Pacific ex Japan ETF (NYSEARCA:EPP) Sees Large Growth in Short Interest
- Godzilla's Rebirth: The Yen Roars And Shakes Up Markets
- Japan Inflation Picks Up as Rate-Boost Bets Firm
- SCENESSE® approved for EPP in Canada
- GondolaBio Announces Positive Phase 2a Results Demonstrating 79% Plasma Protoporphyrin IX Reduction and Disease-Modifying Potential of PORT-77 for Erythropoietic Protoporphyria
- Why Japan's $70 billion-plus intervention and a rate hike didn't prop up the yen more
- Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients
Your note
Sign in to keep a note on EPP — it syncs with the Stock Master app.